We recently reported the induction of potent, cross-clade neutralizing antibodies (nAbs) against Human Immunodeficiency Virus type-1 (HIV-1) in rabbits using gp120 based on an M-group consensus sequence. To better characterize these antibodies, 93 hybridomas were generated, which represent the largest panel of monoclonal antibodies (mAbs) ever generated from a vaccinated rabbit. The single most frequently recognized epitope of the isolated mAbs was at the very C-terminal end of the protein (APTKAKRRVVEREKR), followed by the V3 loop. A total of seven anti-V3 loop mAbs were isolated, two of which (10A3 and 10A37) exhibited neutralizing activity. In contrast to 10A3 and most other anti-V3 loop nAbs, 10A37 was atypical with its epitope position...
AbstractRabbits were immunized with a novel regimen designed to focus the immune response on a singl...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
<div><p>Development of a vaccine for HIV-1 requires a detailed understanding of the neutralizing ant...
The V3 loop of HIV-1 gp120 is an immunodominant region targeted by neutralizing antibodies (nAbs). D...
The V3 loop of HIV-1 gp120 is an immunodominant region targeted by neutralizing antibodies (nAbs). D...
Since its discovery in 1981, HIV-1 has infected almost 78 million people, and ~39 million people hav...
The rabbit is a commonly used animal model in studying antibody responses in HIV/AIDS vaccine develo...
AbstractStudies were performed to induce cross-clade neutralizing antibodies (Abs) by testing variou...
The rabbit is a commonly used animal model in studying antibody responses in HIV/AIDS vaccine develo...
The majority of available monoclonal antibodies (MAbs) in the current HIV vaccine field are generate...
Trimeric HIV-1 envelope (Env) immunogens are attractive due to their ability to display quaternary e...
AbstractOne strategy being evaluated for HIV-1 vaccine development is focusing immune responses towa...
Strong antibody (Ab) responses against V1V2 epitopes of the human immunodeficiency virus type 1 (HIV...
The V1V2 region of HIV-1 gp120 harbors a major vulnerable site targeted by a group of broadly neutra...
Evaluating the structure-function relationship of viral envelope (Env) evolution and the development...
AbstractRabbits were immunized with a novel regimen designed to focus the immune response on a singl...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
<div><p>Development of a vaccine for HIV-1 requires a detailed understanding of the neutralizing ant...
The V3 loop of HIV-1 gp120 is an immunodominant region targeted by neutralizing antibodies (nAbs). D...
The V3 loop of HIV-1 gp120 is an immunodominant region targeted by neutralizing antibodies (nAbs). D...
Since its discovery in 1981, HIV-1 has infected almost 78 million people, and ~39 million people hav...
The rabbit is a commonly used animal model in studying antibody responses in HIV/AIDS vaccine develo...
AbstractStudies were performed to induce cross-clade neutralizing antibodies (Abs) by testing variou...
The rabbit is a commonly used animal model in studying antibody responses in HIV/AIDS vaccine develo...
The majority of available monoclonal antibodies (MAbs) in the current HIV vaccine field are generate...
Trimeric HIV-1 envelope (Env) immunogens are attractive due to their ability to display quaternary e...
AbstractOne strategy being evaluated for HIV-1 vaccine development is focusing immune responses towa...
Strong antibody (Ab) responses against V1V2 epitopes of the human immunodeficiency virus type 1 (HIV...
The V1V2 region of HIV-1 gp120 harbors a major vulnerable site targeted by a group of broadly neutra...
Evaluating the structure-function relationship of viral envelope (Env) evolution and the development...
AbstractRabbits were immunized with a novel regimen designed to focus the immune response on a singl...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
<div><p>Development of a vaccine for HIV-1 requires a detailed understanding of the neutralizing ant...